الصفحة الرئيسية>>(S,R,S)-AHPC-Me dihydrochloride

(S,R,S)-AHPC-Me dihydrochloride (Synonyms: VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride)

رقم الكتالوجGC60426

(S ، R ، S) -AHPC-Me ثنائي هيدروكلوريد (VHL ligand 2 dihydrochloride) هو (S ، R ، S) - Ligand القائم على AHPC المستخدم في توظيف بروتين von Hippel-Lindau (VHL)(S ، R ، S) -AHPC-Me ثنائي هيدروكلوريد يمكن استخدامه لتخليق ARV-771 ، وهو مطهر BET PROTAC يعتمد على von Hippel-Landau (VHL) E3يحلل ARV-771 بروتين BET بشكل فعال في خلايا سرطان البروستاتا المقاومة للإخصاء (CRPC) مع DC50 <1 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

(S,R,S)-AHPC-Me dihydrochloride التركيب الكيميائي

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
50٫00
متوفر
100mg
45٫00
متوفر
500mg
135٫00
متوفر
1g
216٫00
متوفر
2g
347٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein[1]. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM[2].

[1]. Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9.

مراجعات

Review for (S,R,S)-AHPC-Me dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (S,R,S)-AHPC-Me dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.